^
Association details:
Biomarker:GRIN2A mutation
Cancer:Solid Tumor
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Excerpt:
Eighty-one pts received IO who had NGS sent prior to treatment....Most common gene mutations in CR group were ROS1 (52.6%), LRP1B (52.6%), GRIN2A (47.4%), and EPHA7 (42.1%) in 19 patients...
DOI:
10.1200/JCO.2020.38.15_suppl.e15226